Drug Profile
K 22097
Alternative Names: K22.097Latest Information Update: 18 Jul 2002
Price :
$50
*
At a glance
- Originator Klinge Pharma
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 27 Jul 2001 This compound is still in active development
- 07 Feb 2001 Klinge Pharma has been acquired by Fujisawa
- 11 Mar 1998 Preclinical development for Cancer in Germany (Unknown route)